{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113883.3.1444.3.177",
  "meta": {
    "versionId": "6",
    "lastUpdated": "2021-03-19T01:00:22.000-04:00"
  },
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.177",
  "version": "20210319",
  "name": "Immunotherapy Administration",
  "status": "active",
  "date": "2021-03-19T01:00:22-04:00",
  "publisher": "American Society of Clinical Oncology Steward",
  "compose": {
    "include": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version": "2022",
        "concept": [
          {
            "code": "Q2041",
            "display": "Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose"
          },
          {
            "code": "Q2042",
            "display": "Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose"
          }
        ]
      }
    ]
  }
}